Impact News +++ New Fortress Energy secures $4B LNG supply deal with Puerto Rico (SeekingAlpha) +++ NEW FORTRESS ENERGY Aktie +4,20%

SOLENO Aktie

>SOLENO Aktienkurs

41.72 EUR -4.1% (Tradegate)

Ask: 42.72 EUR / 300 Stück

Bid: 42.1 EUR / 200 Stück

Tagesumsatz: 626 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

SOLENO Aktie über LYNX handeln

Intraday

1 Jahr

>SOLENO Performance

1 Woche: -27,8%

1 Monat: -27,2%

3 Monate: -35,8%

6 Monate: -2,9%

1 Jahr: -7,7%

laufendes Jahr: +3,4%

>SOLENO Aktie

Name:

SOLENO THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8342033094 / A3DS0P

Symbol/ Ticker:

6XC (Frankfurt) / SLNO (NASDAQ)

Kürzel:

FRA:6XC, ETR:6XC, 6XC:GR, NASDAQ:SLNO

Index:

Webseite:

https://soleno.life/

Profil:

Soleno Therapeutics Inc. is a biopharmaceutical co..
>Volltext..

Marktkapitalisierung:

2306.17 Mio. EUR

Unternehmenswert:

2107.95 Mio. EUR

Umsatz:

27.69 Mio. EUR

EBITDA:

-156.31 Mio. EUR

Nettogewinn:

-153.56 Mio. EUR

Gewinn je Aktie:

-3.52 EUR

Schulden:

44.75 Mio. EUR

Liquide Mittel:

64.87 Mio. EUR

Operativer Cashflow:

-71.67 Mio. EUR

Bargeldquote:

13.7

Umsatzwachstum:

Gewinnwachstum:

-151.73%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SOLENO

Letzte Datenerhebung:

16.09.25

>SOLENO Kennzahlen

Aktien/ Unternehmen:

Aktien: 53.15 Mio. St.

Frei handelbar: 86.6%

Leerverk. Aktien: 17.58%

Rückkaufquote: -1.05%

Mitarbeiter: 92

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 124.13%

Bewertung:

KGV: -

KGV lG: -

KUV: 91.1

KBV: 11.19

PEG-Ratio: -0.2

EV/EBITDA: -

Rentabilität:

Bruttomarge: 93.25%

Gewinnmarge: -554.49%

Operative Marge: -570.55%

Managementeffizenz:

Gesamtkaprendite: -56.9%

Eigenkaprendite: -69.53%

>SOLENO Peer Group

Es sind 601 Aktien bekannt.

>SOLENO Chart & Kurs - NASDAQ

>SOLENO News

13.09.25 - 20:48	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.- SLNO (PR Newswire)
	NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

12.09.25 - 21:03	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued......

10.09.25 - 19:48	Soleno drops on death of patient treated with Vykat XR (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.09.25 - 21:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

05.09.25 - 20:51	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have......

03.09.25 - 16:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

27.08.25 - 14:03	Soleno Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire EN)
	REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September:...

26.08.25 - 04:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

22.08.25 - 16:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

20.08.25 - 22:03	Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman (PR Newswire)
	SAN FRANCISCO, Aug. 20, 2025 /PRNewswire/ -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an......

15.08.25 - 15:45	Soleno Therapeutics stock falls after Scorpion Capital short report (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

15.08.25 - 15:24	Soleno Therapeutics plunges after short report from Scorpion Capital (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.08.25 - 15:15	BREAKING: Soleno Therapeutics nach Short-Report massiv unter Beschuss (Der Aktionaer)
	"Der größte reine Biotech-Betrug in den USA gemessen an der Marktkapitalisierung", hat Scorpion Capital vor Kurzem auf der Kurznachrichtenplattform X geschrieben. Der aktivistische Leerverkäufer knöpft sich in einem neuen Short-Report die Biotechnologie-Gesellschaft Soleno Therapeutics vor und erhebt schwere Vorwürfe....

11.08.25 - 17:30	How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% (Zacks)
	The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

07.08.25 - 09:06	Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.25 - 03:00	Soleno (SLNO) Q2 Revenue Jumps 30% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 22:03	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results (GlobeNewswire EN)
	REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025....

05.08.25 - 23:21	Soleno Therapeuticss Earnings: A Preview (Benzinga)
	read more...

28.07.25 - 14:03

Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET (GlobeNewswire EN)

REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations....

25.07.25 - 19:45	Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy? (Zacks)
	Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Entschulde dich durch Gott: Die Unschuld bleibt bewehrt und wird in Ewigkeit durch keine Glut verzehrt. - Angelus Silesius

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram